Tenderwize
Zurück zur Suche

Open House Originale Rabattverträge 2024-13 - Apremilast

Techniker Krankenkasse·Hamburg, Germany·Deadline Dec 29, 2026 · 127 days left·Open·Supplies
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2024-13 - Apremilast

46/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

46 / 100

Komplexität

58 / 100

Risikofaktoren

Portal submission is not allowed; contracts must be sent by email with qualified electronic signature or by post, which...

Participation is limited to pharmaceutical entrepreneurs meeting the AMG and reliability requirements for the relevant...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Dec 2026
  • Conclude Open House rebate agreements for the active substance Apremilast.
  • Provide supply of pharmaceutical products under uniform contract conditions.
Vollständige Zusammenfassung anzeigen

This is a German Open House pharmaceutical supply arrangement for Apremilast (CPV 33600000) led by Techniker Krankenkasse, with HEK, hkk and KKH listed as participating buyers. It is not a standard competitive award procedure: all eligible pharmaceutical companies meeting the stated conditions may join on uniform terms, with no exclusivity and no individual negotiations. The contract term runs from 01.01.2025 to 31.12.2026 at the latest, with possible earlier automatic end on patent/market exclusivity expiry. No contract value is provided in the structured data or XML. Submission is not via the portal; contracts must be sent by email with qualified electronic signature or by post, and the documents indicate a special deadline for 1 January 2025 inclusion.

Risiken

Portal submission is not allowed; contracts must be sent by email with qualified electronic signature or by post, which...

Participation is limited to pharmaceutical entrepreneurs meeting the AMG and reliability requirements for the relevant...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Applicant must be a pharmaceutical entrepreneur within the meaning of German medicines law for the offered medicinal products.
  • Applicant must have its seat in the AMG scope, another EU Member State, or another EEA state.
  • Applicant must hold a valid marketing authorisation for the relevant medicinal product(s) or otherwise be entitled to place them on the market in its own name.

Auftraggeber

Ort

Hamburg, DEU

Kennung

992-80116-93

Tätigkeit

Health

Lose (1)

LOT-0001

Open House Originale Rabattverträge 2024-13 - Apremilast

Open House contract for Apremilast supply/rabatt agreements. Scope is nationwide in Germany. The lot concerns concluding uniform rebate contracts with eligible pharmaceutical companies for the active substance Apremilast. The lot information comes from structured data and XML notice.

SuppliesEU fundedElectronic submission

Ort

DE600, Germany

Dauer

Dec 2024 - Dec 2026

Kategorie

Pharmaceutical products

Frist

Deadline Dec 29, 2026

Vergabedetails

Veröffentlichungsdatum
19 Nov 2024
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
706936-2024

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3